Cladribine for treating relapsing–remitting multiple sclerosis

Technology appraisal guidance
Reference number: TA616
Published: 19 December 2019
Last updated: 21 May 2024

History

Review proposal consultation

Review proposal consultation
Stakeholder matrix (MSWord 32 KB)

Published:

06 March 2024
Review proposal paper (MSWord 41 KB)

Published:

06 March 2024

Final draft guidance

Final draft guidance
Final appraisal document (PDF 281 KB)

Published:

22 November 2019